Roivant Sciences Ltd (ROIV)$29.96
Market Cap: 8.26 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Roivant Sciences Ltd (ROIV).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
-9.0x
EV/FCF, N/A FCF yield
Quality
-6.6%
ROIC, -9183.5% FCF margin
Growth
-19.1%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 18.4x current ratio
Superinvestors
3
Top: David Einhorn (1.9%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
- 3 tracked superinvestors report a position.
Watchouts
- Free cash flow margin is negative at -9183.5%.
- Five-year revenue trend is negative at -19.1%.
Annual data: 6 periods
Quarterly data: 22 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ROIV.
Grade F
10
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| ROIV Target | Roivant Sciences Ltd | $8.3B | -55.5x | -9.0x | -6.6% | -19.1% | -9183.5% | N/A | N/A | N/A |
| TECH | Bio-Techne Corp. | $7.9B | 104.8x | 30.1x | 3.8% | 10.5% | 21.0% | 64.8% | -0.8x | N/A |
| HALO | Halozyme Therapeutics | $7.5B | 26.7x | 14.7x | 14.5% | 39.2% | 46.2% | N/A | 4.2x | N/A |
| BBIO | BridgeBio Pharma Inc. | $7.3B | -18.3x | -19.5x | N/A | 127.4% | -89.0% | N/A | N/A | N/A |
| MRNA | Moderna, Inc. | $10.8B | -6.5x | -4.0x | -32.6% | 19.3% | -106.2% | N/A | N/A | N/A |
| LEGN | Legend Biotech Corp. | $6.1B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | 30.1x | 14.6x | 5.7% | 11.6% | 22.5% | N/A | -2.7x | N/A |
| AXSM | Axsome Therapeutics Inc. | $5.7B | -64.1x | -57.1x | -207.5% | N/A | -14.7% | N/A | N/A | N/A |
| INCY | Incyte Corp. | $12.0B | 15.2x | 6.3x | 24.9% | 14.0% | 27.5% | N/A | -1.9x | N/A |
Financial Charts
No financial data available for ROIV (annual).
3 superinvestors own ROIV
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Viking Global Investors Viking Global Investors | 6,652,448 | $184M | 0.52% | 0.0% |
| David Einhorn Greenlight Capital | 2,152,669 | $60M | 1.87% | 0.0% |
| Lee Ainslie Maverick Capital | 1,626,940 | $45M | 0.52% | 0.0% |